The European market for hormones, prostaglandins, thromboxanes, and leukotrienes saw significant differences in sold production across countries in 2024. Denmark led with 1.7156 billion euros, reflecting a substantial 48.23% year-on-year increase. Sweden and Italy followed, with respective values of 0.9693 and 0.5219 billion euros, both showing growth around 9.5% annually. Germany and France experienced slight declines, demonstrating competitive challenges ahead. Overall, the five-year CAGR indicated varying levels among nations, underscoring diverse market dynamics within Europe.
Future trends to watch:
- Denmark's continued market leadership, driven by innovation and favorable policies.
- Growth potential in Sweden and Italy as they build on recent gains.
- Recovery efforts in Germany and France with potential regulatory impacts.
- Emergent opportunities in underrepresented markets like Hungary and Finland.
Top countries in Sold Production of Hormones, Prostaglandins, Thromboxanes and Leukotrienes by Country
| # | 9 Countries | Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Denmark | 1,715,600,000 | 2023 | +16.34% | +48.23% | View data |
| 2 | 2 Sweden | 969,300,000 | 2023 | +11.77% | +9.51% | View data |
| 3 | 3 Italy | 521,900,000 | 2023 | +2.3% | +9.47% | View data |
| 4 | 4 Germany | 170,890,000 | 2023 | +0.45% | -4.43% | View data |
| 5 | 5 France | 159,180,000 | 2023 | -0.11% | -1.86% | View data |
| 6 | 6 Spain | 136,760,000 | 2023 | +3.82% | +4.77% | View data |
| 7 | 7 Hungary | 72,200,000 | 2023 | +1.08% | +1.06% | View data |
| 8 | 8 Belgium | 11,603,000 | 2021 | +21.01% | View data | |
| 9 | 9 Finland | 570,530 | 2023 | +6.81% | +0.95% | View data |
